Risk adjusted therapy in chronic lymphocytic leukemia: a phase II cancer trials Ireland (CTRIAL-IE [ICORG 07-01]) study of fludarabine, cyclophosphamide, and rituximab therapy evaluating response adapted, abbreviated frontline therapy with FCR in non-del(17p) CLL-Reference-Cited by-同舟云学术

Risk adjusted therapy in chronic lymphocytic leukemia: a phase II cancer trials Ireland (CTRIAL-IE [ICORG 07-01]) study of fludarabine, cyclophosphamide, and rituximab therapy evaluating response adapted, abbreviated frontline therapy with FCR in non-del(17p) CLL

Published:2017-09-19 Issue:6 Volume:59 Page:1338-1347
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Appleby Niamh¹,O’Brien David¹,Quinn Fiona M.²,Smyth Liam¹,Kelly Johanna³,Parker Imelda⁴,Scott Kathleen⁴,Cahill Mary R.⁵,Crotty Gerard⁶,Enright Helen⁷,Hennessy Brian⁸,Hodgson Andrew⁹,Leahy Maeve¹⁰,O’Leary Hilary¹⁰,O’Dwyer Michael¹¹,Hayat Amjad¹¹,Vandenberghe Elisabeth A.¹

Affiliation:

1. Department of Haematology, St. James’s Hospital and Trinity College Dublin, Dublin, Ireland;

2. Department of Cancer Molecular Diagnostics, St. James’s Hospital, Dublin, Ireland;

3. Department of Medical Genetics, Our Lady's Hospital for Children, Dublin, Ireland;

4. Cancer Trials Ireland, Dublin, Ireland;

5. Department of Haematology, Cork University Hospital, Cork, Ireland;

6. Department of Haematology, Midlands Regional Hospital, Tullamore, Ireland;

7. Department of Haematology, Adelaide, Meath and National Children’s Hospital, Dublin, Ireland;

8. Department of Haematology, University Hospital Waterford, Waterford, Ireland;

9. Department of Haematology, Sligo Regional Hospital, Sligo, Ireland;

10. Department of Haematology, University Hospital Limerick, Limerick, Ireland;

11. Department of Haematology, University Hospital Galway, Galway, Ireland

Funder

Cancer Trials Ireland

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Link

https://www.tandfonline.com/doi/pdf/10.1080/10428194.2017.1376746

Reference52 articles.

1. Estimating the prevalence of hematological malignancies and precursor conditions using data from Haematological Malignancy Research Network (HMRN)

2. Early Results of a Chemoimmunotherapy Regimen of Fludarabine, Cyclophosphamide, and Rituximab As Initial Therapy for Chronic Lymphocytic Leukemia

3. Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia

4. Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia

5. Eradication of bone marrow minimal residual disease may prompt early treatment discontinuation in CLL

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Evidence-Based Management of Chronic Lymphocytic Leukemia: Consensus Statements from the Gulf Region;Acta Haematologica;2023-09-26

2. Measurable Residual Disease in Chronic Lymphocytic Leukemia: Current Understanding and Evolving Role in Clinical Practice;Current Treatment Options in Oncology;2023-05-17

3. Measurable Residual Disease in Chronic Lymphocytic Leukemia: Experience in Real-Life Setting with Dry Tube Flow Cytometric Method;Namık Kemal Tıp Dergisi;2022-06-22

4. Flow cytometric evaluation of measurable residual disease in chronic lymphocytic leukemia: Where do we stand?;Hematological Oncology;2022-06-21

5. Measurable residual disease in chronic lymphocytic leukemia: expert review and consensus recommendations;Leukemia;2021-06-24